Citation: Cw. Boone et Gj. Kelloff, END-POINT MARKERS FOR CLINICAL-TRIALS OF CHEMOPREVENTIVE AGENTS DERIVED FROM THE PROPERTIES OF EPITHELIAL PRECANCER (INTRAEPITHELIAL NEOPLASIA) MEASURED BY COMPUTER-ASSISTED IMAGE-ANALYSIS, Cancer surveys, 32, 1998, pp. 133-147
Citation: Rtd. Oliver et Mj. Coptcoat, CLONAL EVOLUTION IN BLADDER-CANCER - A SCIENTIFIC AND CLINICAL PERSPECTIVE - INTRODUCTION, Cancer surveys, 31, 1998, pp. 1-3
Citation: J. Landman et Mj. Droller, RISK-FACTORS IN CLONAL DEVELOPMENT FROM SUPERFICIAL TO INVASIVE BLADDER-CANCER, Cancer surveys, 31, 1998, pp. 5-15
Citation: S. Baithun et al., SQUAMOUS CHANGE IN BLADDER-CANCER AND ITS RELEVANCE TO UNDERSTANDING CLONAL EVOLUTION IN DEVELOPMENT OF BLADDER-CANCER, Cancer surveys, 31, 1998, pp. 17-27
Citation: Dl. Lamm, CLINICAL-EVALUATION OF IMMUNOTHERAPY - ARE THERE DIFFERENCES BETWEEN PAPILLARY AND FLAT IN-SITU BLADDER-CANCER, Cancer surveys, 31, 1998, pp. 99-108
Citation: Ame. Nouri et al., CLONAL DEVELOPMENT OF BLADDER-CANCER AND ITS RELEVANCE TO THE CLINICAL POTENTIAL OF HLA-ANTIGEN AND TP53 BASED GENE-THERAPY, Cancer surveys, 31, 1998, pp. 109-128